147 related articles for article (PubMed ID: 37884606)
1. Application of statistical machine learning in biomarker selection.
Vashistha R; Noor Z; Dasgupta S; Pu J; Deng S
Sci Rep; 2023 Oct; 13(1):18331. PubMed ID: 37884606
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma.
Grivas P; Kopyltsov E; Su PJ; Parnis FX; Park SH; Yamamoto Y; Fong PC; Tournigand C; Climent Duran MA; Bamias A; Caserta C; Chang J; Cislo P; di Pietro A; Wang J; Powles T
Eur Urol; 2023 Apr; 83(4):320-328. PubMed ID: 35654659
[TBL] [Abstract][Full Text] [Related]
3. Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer.
Powles T; Park SH; Voog E; Caserta C; Valderrama BP; Gurney H; Kalofonos H; Radulovic S; Demey W; Ullén A; Loriot Y; Sridhar SS; Tsuchiya N; Kopyltsov E; Sternberg CN; Bellmunt J; Aragon-Ching JB; Petrylak DP; Laliberte RJ; Huang B; Costa N; Blake-Haskins JA; Grivas P
Future Oncol; 2022 Jun; 18(19):2361-2371. PubMed ID: 35416053
[TBL] [Abstract][Full Text] [Related]
4. Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysis.
Lee JL; Desai C; Park SH; Tsuchiya N; Su PJ; Chan TTW; Gurney H; Gao S; Wang J; Sandner R; di Pietro A; Eto M
Urol Oncol; 2023 May; 41(5):256.e17-256.e25. PubMed ID: 37019764
[TBL] [Abstract][Full Text] [Related]
5. Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up.
Powles T; Park SH; Caserta C; Valderrama BP; Gurney H; Ullén A; Loriot Y; Sridhar SS; Sternberg CN; Bellmunt J; Aragon-Ching JB; Wang J; Huang B; Laliberte RJ; di Pietro A; Grivas P
J Clin Oncol; 2023 Jul; 41(19):3486-3492. PubMed ID: 37071838
[No Abstract] [Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. A cost-effectiveness analysis of avelumab plus best supportive care versus best supportive care alone as first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma in Taiwan.
Su PJ; Xiao Y; Lin AY; Goh C; Wu E; Liu K; Chou P; Kuo K; Palencia R; Chang J; Kearney M; Kapetanakis V; Benedict A
Cancer Rep (Hoboken); 2023 Oct; 6(10):e1887. PubMed ID: 37640556
[TBL] [Abstract][Full Text] [Related]
8. Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis.
Tomita Y; Yamamoto Y; Tsuchiya N; Kanayama H; Eto M; Miyake H; Powles T; Yoshida M; Koide Y; Umeyama Y; di Pietro A; Uemura H
Int J Clin Oncol; 2022 Feb; 27(2):383-395. PubMed ID: 34973108
[TBL] [Abstract][Full Text] [Related]
9. Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial.
Powles T; Sridhar SS; Loriot Y; Bellmunt J; Mu XJ; Ching KA; Pu J; Sternberg CN; Petrylak DP; Tambaro R; Dourthe LM; Alvarez-Fernandez C; Aarts M; di Pietro A; Grivas P; Davis CB
Nat Med; 2021 Dec; 27(12):2200-2211. PubMed ID: 34893775
[TBL] [Abstract][Full Text] [Related]
10. Variable selection in social-environmental data: sparse regression and tree ensemble machine learning approaches.
Handorf E; Yin Y; Slifker M; Lynch S
BMC Med Res Methodol; 2020 Dec; 20(1):302. PubMed ID: 33302880
[TBL] [Abstract][Full Text] [Related]
11. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
Powles T; Park SH; Voog E; Caserta C; Valderrama BP; Gurney H; Kalofonos H; Radulović S; Demey W; Ullén A; Loriot Y; Sridhar SS; Tsuchiya N; Kopyltsov E; Sternberg CN; Bellmunt J; Aragon-Ching JB; Petrylak DP; Laliberte R; Wang J; Huang B; Davis C; Fowst C; Costa N; Blake-Haskins JA; di Pietro A; Grivas P
N Engl J Med; 2020 Sep; 383(13):1218-1230. PubMed ID: 32945632
[TBL] [Abstract][Full Text] [Related]
12. Can Predictive Modeling Tools Identify Patients at High Risk of Prolonged Opioid Use After ACL Reconstruction?
Anderson AB; Grazal CF; Balazs GC; Potter BK; Dickens JF; Forsberg JA
Clin Orthop Relat Res; 2020 Jul; 478(7):0-1618. PubMed ID: 32282466
[TBL] [Abstract][Full Text] [Related]
13. Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice.
Grivas P; Grande E; Davis ID; Moon HH; Grimm MO; Gupta S; Barthélémy P; Thibault C; Guenther S; Hanson S; Sternberg CN
ESMO Open; 2023 Dec; 8(6):102050. PubMed ID: 37976999
[TBL] [Abstract][Full Text] [Related]
14. Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice.
Grivas P; Agarwal N; Pal S; Kalebasty AR; Sridhar SS; Smith J; Devgan G; Sternberg CN; Bellmunt J
Cancer Treat Rev; 2021 Jun; 97():102187. PubMed ID: 33839438
[TBL] [Abstract][Full Text] [Related]
15. Towards precision medicine: Accurate predictive modeling of infectious complications in combat casualties.
Dente CJ; Bradley M; Schobel S; Gaucher B; Buchman T; Kirk AD; Elster E
J Trauma Acute Care Surg; 2017 Oct; 83(4):609-616. PubMed ID: 28538622
[TBL] [Abstract][Full Text] [Related]
16. A comparative study of forest methods for time-to-event data: variable selection and predictive performance.
Liu Y; Zhou S; Wei H; An S
BMC Med Res Methodol; 2021 Sep; 21(1):193. PubMed ID: 34563138
[TBL] [Abstract][Full Text] [Related]
17. Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance.
Sridhar SS; Powles T; Climent Durán MÁ; Park SH; Massari F; Thiery-Vuillemin A; Valderrama BP; Ullén A; Tsuchiya N; Aragon-Ching JB; Gupta S; Petrylak DP; Bellmunt J; Wang J; Laliberte RJ; di Pietro A; Costa N; Grivas P; Sternberg CN; Loriot Y
Eur Urol; 2024 Feb; 85(2):154-163. PubMed ID: 37714742
[TBL] [Abstract][Full Text] [Related]
18. Part 1. Statistical Learning Methods for the Effects of Multiple Air Pollution Constituents.
Coull BA; Bobb JF; Wellenius GA; Kioumourtzoglou MA; Mittleman MA; Koutrakis P; Godleski JJ
Res Rep Health Eff Inst; 2015 Jun; (183 Pt 1-2):5-50. PubMed ID: 26333238
[TBL] [Abstract][Full Text] [Related]
19. Variable selection with missing data in both covariates and outcomes: Imputation and machine learning.
Hu L; Joyce Lin JY; Ji J
Stat Methods Med Res; 2021 Dec; 30(12):2651-2671. PubMed ID: 34696650
[TBL] [Abstract][Full Text] [Related]
20. Bayesian two-step Lasso strategy for biomarker selection in personalized medicine development for time-to-event endpoints.
Gu X; Yin G; Lee JJ
Contemp Clin Trials; 2013 Nov; 36(2):642-50. PubMed ID: 24075829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
